Aspira Women`s Health Inc Stock News

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations. Mr. Buhle has over 25 years of experience d...

CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition

The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award

Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Ear...

Management to Announce Earnings Results and hold a call at 8:30 am ET Management to Announce Earnings Results and hold a call at 8:30 am ET

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline

Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis

New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State